Saturday 17 October 2026
Export ERNA’s income statement to Excel — free account
Ernexa Therapeutics Inc.
ERNA Healthcare Biotechnology
Ernexa Therapeutics Inc.’s revenue for fiscal 2024 (year ended December 2024) was $582,000.00, up 755.9% from fiscal 2023. In the quarter to June 2026, revenue fell 94.1%, EPS grew 77.7% and free cash flow fell 64.1%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
2.09
0.08
−3.69%
Follow ERNA
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Jan '22 | Dec '21 | Jan '21 | Dec '20 | Jan '20 | Dec '19 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | 0.00 | 0.00 | — | — | — | — | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
— | — | — | — | — | — | — | — | — | 4 |
P/S ratio |
— | 6.80 | 3.68 | — | — | — | — | 13.32 | 0.34 | 0.33 |
Altman Z-Score |
— | (70.69) | (6.55) | — | — | — | — | 5.34 | — | (11.60) |
Altman Z″-Score (non-manufacturers) |
— | (163.47) | (14.84) | — | — | — | — | (7.53) | — | (30.60) |
P/FCF ratio |
— | 0.00 | 0.00 | — | — | — | — | 0.00 | 3.98 | 3.93 |
Beneish M-Score |
— | (24.48) | — | — | — | — | — | — | — | (3.74) |
P/Operating CF |
— | (1.12) | (2.15) | — | — | — | — | (47.19) | 6.81 | 6.71 |
P/B ratio |
— | 2.33 | 4.49 | — | — | — | — | 10.09 | 1.31 | 1.30 |
Price to Tangible BV |
— | 0.00 | 53.25 | — | — | — | — | 13.76 | 1.52 | 1.50 |
EV/Sales |
— | 59.41 | 3.50 | — | — | — | — | 13.10 | 0.31 | 0.31 |
EV/EBITDA |
— | 0.00 | 0.00 | — | — | — | — | 0.00 | 3.15 | 3.10 |
EV/Operating CF |
— | (2.18) | (0.47) | — | — | — | — | (9.38) | 2.26 | 2.22 |
EV/FCF |
— | (2.13) | (0.47) | — | — | — | — | (9.33) | 3.69 | 3.63 |
Quick Ratio |
0.64 | 0.74 | 1.22 | 1.62 | 1.62 | 4.81 | 4.81 | 0.56 | 0.00 | 0.73 |
Current Ratio |
1.01 | 0.80 | 1.46 | 1.79 | 1.79 | 5.10 | 5.10 | 0.55 | 0.55 | 1.00 |
Net Debt/EBITDA |
0.21 | 0.20 | 0.04 | 0.35 | 0.00 | 0.15 | 0.00 | 0.18 | (0.18) | (0.25) |
Debt/Assets |
0.00% | 0.00% | 13.79% | 0.00% | 0.00% | 0.00% | 0.00% | 2.40% | 21.04% | 19.53% |
Debt/Equity |
0.00 | 0.00 | 3.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | (0.25) | 0.54 |
Asset Turnover |
0.00 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.43 | 0.42 | 1.37 |
Operating CF/Net income |
0.50 | 0.36 | 0.94 | 0.85 | 0.85 | 0.19 | 0.19 | 1.11 | 0.31 | (1.33) |
Capex/Depreciation |
(0.14) | (0.05) | (0.01) | (0.09) | 0.00 | (0.34) | 0.00 | (0.40) | 0.00 | (0.29) |
Interest Coverage |
(345.15) | (2.32) | (34.42) | (1,107.23) | — | — | — | (52.52) | — | (7.08) |
| (687.80%) | (2,266.28%) | (302.47%) | (130.80%) | 0.00% | (739.19%) | 0.00% | (114.38%) | 0.00% | (34.37%) | |
| (253.99%) | (163.80%) | (60.73%) | (91.42%) | 0.00% | (551.69%) | 0.00% | (53.95%) | 0.00% | (14.23%) | |
ROIC |
(1,126.57%) | 0.00% | (923.09%) | (3,140.79%) | 0.00% | (834.50%) | 0.00% | (71.46%) | 0.00% | (23.99%) |
Return on Tangible Assets |
(12,368.42%) | 8,893.21% | (616.20%) | (392.70%) | (337.24%) | (777.72%) | (668.78%) | 912.52% | (2,050.31%) | (73.76%) |
Average Days of Receivables |
0.00 | 274.06 | 2,281.25 | 0.00 | 0.00 | 0.00 | 0.00 | 7.30 | 7.30 | 22.02 |
Research and Development Expense of Revenue |
0.00% | 791.07% | 8,705.88% | 0.00% | 0.00% | 0.00% | 0.00% | 68.12% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 2,256.36% | 21,451.47% | 0.00% | 0.00% | 0.00% | 0.00% | 56.84% | 0.00% | 66.52% |
Intangible Assets out of Total Assets |
0.35 | 0.39 | 0.04 | 0.09 | 0.09 | 0.06 | 0.25 | 0.16 | 0.65 | 0.05 |
Share Based Compensation of Revenue |
0.00% | 261.17% | 1,826.47% | 0.00% | — | 0.00% | — | 1.57% | 0.00% | 1.04% |
Graham Net Nets |
— | (0.31) | (3.73) | — | — | — | — | (0.05) | (0.44) | (0.45) |
Graham Number |
— | 0.00 | 0.00 | — | — | — | — | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | (1,126.63%) | (216.91%) | — | — | — | — | (9.25%) | (31.82%) | (32.26%) |
Free Cash Flow Yield |
— | (409.27%) | (204.06%) | — | — | — | — | (10.53%) | 25.10% | 25.44% |
Revenue per Share |
0.00 | 15.99 | 4.79 | 0.00 | 0.00 | 0.00 | 0.00 | 2,521.74 | 0.00 | 99,030.00 |
Operating CF per Share |
(27.81) | (435.05) | (1,437.18) | (2,589.63) | (6.88) | (4,049.66) | (10.85) | (3,522.17) | (18.42) | 13,720.00 |
Capex per Share |
(0.15) | (10.03) | (1.34) | (5.80) | 0.00 | (26.55) | 0.00 | (16.96) | 0.00 | (5,325.00) |
Free Cash Flow per Share |
(27.96) | (445.08) | (1,438.52) | (2,595.43) | (6.88) | (4,076.21) | (10.85) | (3,539.13) | (18.42) | 8,395.00 |
Cash per Share |
7.47 | 47.50 | 533.45 | 1,413.09 | 3.75 | 2,928.45 | 7.85 | 708.70 | 3.71 | 16,295.00 |
Shareholders Equity per Share |
9.52 | 46.73 | 157.25 | 1,494.69 | 3.97 | 4,397.07 | 11.78 | 3,330.00 | (26.34) | 25,455.00 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
Book value per Share |
9.52 | 46.73 | 157.25 | 1,494.69 | 3.97 | 4,397.07 | 11.78 | 3,330.00 | (26.34) | 25,455.00 |
Free Cash Flow |
(7.05) | (16.20) | (20.43) | (21.02) | (20.98) | (23.64) | (23.49) | (8.14) | (8.10) | 1.68 |
Working Capital |
0.02 | (0.59) | 3.03 | 6.03 | 6.03 | 15.09 | 15.09 | (1.39) | (1.39) | (0.02) |
Capital Expenditures |
(0.04) | (0.36) | (0.02) | (0.05) | (0.30) | (0.15) | (0.15) | (0.04) | (0.04) | (1.06) |
Net Current Asset Value |
(0.30) | (1.22) | (37.30) | 3.51 | 3.51 | 12.74 | 12.74 | (3.51) | (23.62) | (2.96) |
EV/EBIT |
— | 0.00 | 0.00 | — | — | — | — | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.63 | 0.28 | 0.00 | — | 0.00 | — | 0.01 | 0.00 | 0.05 |
Price to Operating Income |
— | 0.00 | 0.00 | — | — | — | — | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
2.80 | 81.14 | 2.89 | 2.11 | 0.39 | 0.69 | 0.14 | 0.17 | 0.04 | 1.32 |
Cash ROIC |
(164.62%) | (472.33%) | (123.20%) | (89.26%) | 0.00% | (55.64%) | 0.00% | (84.80%) | 114.86% | 15.11% |
Accounts Receivable Turnover |
0.00 | 1.35 | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 | 50.00 | 8.85 | 16.94 |
Accounts Payable Turnover |
0.00 | 0.07 | 0.18 | 0.00 | 0.29 | 0.00 | 0.30 | 2.76 | 0.09 | 13.53 |
Inventory Turnover |
— | 0.00 | 0.00 | — | 0.00 | — | 0.00 | 0.00 | 0.11 | 0.00 |
Average Days of Payables |
0.00 | 6,543.39 | 1,650.23 | 0.00 | 0.00 | 0.00 | 0.00 | 160.09 | 0.00 | 40.73 |
Days of Inventory on Hand |
— | 0.00 | 0.00 | — | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
0.27 | 0.43 | 0.69 | 0.82 | 0.82 | 0.40 | 0.40 | 0.12 | 0.66 | 1.17 |
Average Payables |
1.42 | 1.39 | 1.34 | 1.69 | 1.69 | 1.52 | 1.52 | 1.06 | 1.06 | 0.55 |
Average Inventory |
— | — | — | — | — | — | — | — | 0.87 | — |
Average Assets |
5.55 | 27.20 | 35.71 | 26.90 | 26.90 | 22.22 | 22.22 | 13.52 | 13.95 | 14.49 |
Average Common Equity |
2.05 | 1.97 | 7.17 | 18.80 | 18.80 | 16.58 | 16.58 | 6.37 | (3.25) | 6.00 |
Columns are period end dates